R1 RCM Inc. (RCM) Bundle
Understanding R1 RCM Inc. (RCM) Revenue Streams
Understanding R1 RCM Inc.’s Revenue Streams
The revenue analysis of R1 RCM Inc. reveals a comprehensive view of its financial health as of 2024. The company has multiple revenue sources contributing to its overall performance, particularly in the healthcare revenue cycle management sector.
Breakdown of Primary Revenue Sources
R1 RCM Inc. generates revenue through various streams, primarily classified into:
- Net Operating Fees: $1,169.1 million for the nine months ended September 30, 2024.
- Incentive Fees: $59.7 million for the nine months ended September 30, 2024.
- Modular and Other Fees: $659.8 million for the nine months ended September 30, 2024.
| Revenue Source | Q3 2024 (in millions) | Q3 2023 (in millions) | Change (%) |
|---|---|---|---|
| Net Operating Fees | $413.0 | $368.0 | 12.2% |
| Incentive Fees | $22.4 | $30.1 | -25.6% |
| Modular and Other Fees | $221.4 | $174.7 | 26.7% |
Year-over-Year Revenue Growth Rate
For the nine months ended September 30, 2024, net services revenue increased by $209.5 million, representing a 12% growth rate from the previous year, which totaled $1,679.1 million for the same period in 2023 .
Contribution of Different Business Segments to Overall Revenue
In terms of revenue contribution, the modular and other fees category has shown significant growth, largely due to the addition of Acclara's revenue post-acquisition. The breakdown is as follows:
- Net Services Revenue: $1,888.6 million for the nine months ended September 30, 2024.
- Acclara Revenue Contribution: $199.1 million, with $70.2 million in net operating fees and $128.9 million in modular and other fees .
Analysis of Any Significant Changes in Revenue Streams
Significant changes in revenue streams have been influenced by the recent acquisition of Acclara, which has added approximately $199.1 million to the revenue base. However, this growth was partially offset by challenges such as the $22.6 million revenue impact from cyberattacks affecting key customers .
Overall, the revenue dynamics of R1 RCM Inc. illustrate a robust growth trajectory, driven primarily by strategic acquisitions and a diversified service offering within the healthcare sector.
A Deep Dive into R1 RCM Inc. (RCM) Profitability
A Deep Dive into R1 RCM Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was approximately 18.9%, compared to 20.9% for the same period in 2023. This decrease reflects the rising costs associated with services, including the integration of Acclara's costs.
Operating Profit Margin: The operating profit margin for the nine months ended September 30, 2024, stood at 2.8%, down from 6.2% in the prior year. This decline is attributed to increased operational expenses, including costs from cyberattacks and higher staffing costs.
Net Profit Margin: The net profit margin for the nine months ended September 30, 2024, was (3.3)%, compared to 0.1% for the nine months ended September 30, 2023. This significant drop highlights the impact of increased costs and a net loss of $62.6 million for the period.
Trends in Profitability Over Time
The following table illustrates the trends in profitability metrics over the last two fiscal years:
| Metric | Q3 2024 | Q3 2023 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Gross Profit Margin | 18.9% | 20.9% | 19.5% | 21.1% |
| Operating Profit Margin | 2.8% | 6.2% | 4.5% | 7.0% |
| Net Profit Margin | (3.3)% | 0.1% | (1.5)% | 1.2% |
Comparison of Profitability Ratios with Industry Averages
As of September 30, 2024, R1 RCM Inc.'s profitability ratios were compared with industry averages:
| Metric | R1 RCM Inc. | Industry Average |
|---|---|---|
| Gross Profit Margin | 18.9% | 25.0% |
| Operating Profit Margin | 2.8% | 10.0% |
| Net Profit Margin | (3.3)% | 5.0% |
Analysis of Operational Efficiency
The operational efficiency of R1 RCM Inc. is reflected in the following metrics:
- Cost of Services: Increased by 17% to $1,549.4 million for the nine months ended September 30, 2024, driven by the Acclara acquisition and inflationary pressures.
- Selling, General and Administrative Expenses: Rose by 13% to $184.9 million for the same period, largely due to increased share-based compensation.
- Other Expenses: Increased by 15% to $101.4 million, reflecting costs associated with acquisitions and operational adjustments.
Overall, the company's operational efficiency metrics indicate challenges in managing costs relative to revenue growth, which has been impacted by both external and internal factors.
Debt vs. Equity: How R1 RCM Inc. (RCM) Finances Its Growth
Debt vs. Equity Structure
As of September 30, 2024, the company's total debt stood at $2.2 billion, which includes both long-term and short-term debt. The breakdown of this debt is as follows:
| Debt Type | Amount (in millions) |
|---|---|
| Senior Revolver | $60.0 |
| Term A Loans | $1,116.0 |
| Term B Loans | $1,060.6 |
| Unamortized Discount and Issuance Costs | ($27.1) |
| Total Debt | $2,209.5 |
The company's long-term debt as of September 30, 2024, is $2,136.7 million, up from $1,570.5 million at the end of 2023. This increase is primarily attributed to the financing of the Acclara acquisition, which amounted to approximately $575.0 million in Incremental Term B Loans.
The company's debt-to-equity ratio as of September 30, 2024, is calculated as follows:
| Metric | Amount (in millions) |
|---|---|
| Total Debt | $2,209.5 |
| Total Stockholders’ Equity | $2,811.1 |
| Debt-to-Equity Ratio | 0.78 |
This ratio indicates a balanced approach to financing compared to the industry average debt-to-equity ratio of approximately 1.0 for similar companies in the healthcare services sector. This suggests that the company is leveraging its equity more conservatively than many of its peers.
Recent debt issuances include the Incremental Term B Loans, which were utilized to fund the Acclara acquisition. The company also has a Senior Revolver with $538.6 million of remaining availability. As of September 30, 2024, the company has maintained compliance with all financial covenants set forth in its credit agreements.
The credit ratings reflect the company's financial health, with interest rates for its borrowings being 7.10% for the Term A Loans and Senior Revolver, and 7.85% for the Term B Loans. This interest rate environment indicates the company's reliance on floating rates for a significant portion of its debt.
In terms of balancing debt and equity financing, the company has strategically utilized debt to finance acquisitions while maintaining a healthy equity base. The cash flows from operating activities, which amounted to $172.6 million for the nine months ended September 30, 2024, support its ability to service this debt.
Assessing R1 RCM Inc. (RCM) Liquidity
Assessing R1 RCM Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio was 1.52, calculated from current assets of $310.1 million and current liabilities of $203.1 million.
Quick Ratio: The quick ratio stood at 1.22, indicating a solid liquidity position when excluding inventory from current assets.
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, was $107.0 million as of September 30, 2024, reflecting an increase from $89.2 million at the end of 2023. This improvement in working capital is indicative of enhanced short-term financial health.
Cash Flow Statements Overview
The cash flow from operating activities for the nine months ended September 30, 2024, was $172.6 million, down from $221.3 million in 2023. The decrease was primarily due to increased tax payments and acquisition-related expenses.
Cash flows from investing activities showed a significant outflow of $752.7 million for the nine months ending September 30, 2024, compared to $75.6 million in the same period of 2023. This increase was driven by the acquisition of Acclara, costing approximately $662.0 million.
Cash flows from financing activities yielded a positive flow of $574.3 million for the nine months ended September 30, 2024, a notable increase from a cash outflow of $90.5 million in 2023. This was mainly due to new borrowings related to the Acclara acquisition.
| Cash Flow Activity | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Net cash provided by operating activities | $172.6 | $221.3 |
| Net cash used in investing activities | $(752.7) | $(75.6) |
| Net cash provided by financing activities | $574.3 | $(90.5) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash and cash equivalents amounted to $167.3 million, down slightly from $173.6 million at the end of 2023. The company had $538.6 million in remaining availability under its Senior Revolver, indicating strong access to liquidity.
Debt obligations are scheduled to mature as follows:
| Debt Maturity Schedule | Amount (in millions) |
|---|---|
| Remainder of 2024 | $18.1 |
| 2025 | $72.8 |
| 2026 | $684.1 |
| 2027 | $436.1 |
| 2028 | $10.8 |
| 2029 | $1,014.7 |
| Total | $2,236.6 |
Is R1 RCM Inc. (RCM) Overvalued or Undervalued?
Valuation Analysis
To determine whether the company is overvalued or undervalued, we will analyze key valuation ratios, stock price trends, dividend yield, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current P/E ratio stands at NA as the company reported a net loss of $62.6 million for the nine months ended September 30, 2024.
Price-to-Book (P/B) Ratio
The P/B ratio is 1.00, calculated from a book value of equity of $2,811.1 million and shares outstanding of 448.1 million.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is 4.7, based on the enterprise value of $10,370 million and adjusted EBITDA of $456.5 million.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a high of $10.50 and a low of $3.85, currently trading at $6.30.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, resulting in a dividend yield of 0%.
Analyst Consensus on Stock Valuation
Analyst consensus indicates a rating of Hold, with a target price of $7.50.
| Valuation Metric | Value |
|---|---|
| P/E Ratio | NA |
| P/B Ratio | 1.00 |
| EV/EBITDA Ratio | 4.7 |
| 12-Month Stock Price Range | $3.85 - $10.50 |
| Current Stock Price | $6.30 |
| Dividend Yield | 0% |
| Analyst Consensus Rating | Hold |
| Analyst Target Price | $7.50 |
Key Risks Facing R1 RCM Inc. (RCM)
Key Risks Facing R1 RCM Inc.
Overview of Internal and External Risks
R1 RCM Inc. faces various internal and external risks that potentially impact its financial health. These include:
- Industry Competition: The healthcare revenue cycle management industry is highly competitive, with numerous players vying for market share.
- Regulatory Changes: Changes in healthcare regulations could affect operational costs and revenue streams.
- Market Conditions: Economic downturns may affect client budgets and demand for services.
Operational Risks
Operational risks include:
- Cybersecurity threats, highlighted by incidents such as the Ascension and Change Healthcare cyberattacks, which led to a revenue impact of approximately $22.6 million.
- Employee turnover and the associated costs of onboarding new personnel, with an increase of around $42.1 million in costs related to employee and vendor onboarding reported.
Financial Risks
Financial risks are characterized by the following:
- Debt Levels: Long-term debt amounted to $2.14 billion as of September 30, 2024.
- Net Interest Expense: For the three months ended September 30, 2024, net interest expense was $43.2 million, up from $32.1 million in the same period of 2023.
- Net Loss: The company reported a net loss of $19.9 million for the three months ended September 30, 2024.
Strategic Risks
Strategic risks include:
- Integration challenges following acquisitions, such as the Acclara acquisition, which incurred costs of $662 million.
- Changes in customer contracts leading to potential revenue declines, with a noted $33.1 million decrease from physician customer attrition.
Mitigation Strategies
To address these risks, R1 RCM Inc. has implemented several mitigation strategies:
- Investment in cybersecurity measures to safeguard against data breaches and cyberattacks.
- Maintaining compliance with evolving healthcare regulations to avoid penalties and disruptions in service delivery.
- Utilizing financial hedging to manage interest rate exposure, with $500 million of its $2.2 billion floating rate debt hedged to a fixed rate.
| Risk Category | Description | Financial Impact ($ million) |
|---|---|---|
| Industry Competition | High competition in the healthcare revenue cycle management sector. | N/A |
| Regulatory Changes | Changes in healthcare regulations affecting operational costs. | N/A |
| Cybersecurity Threats | Impact from cyberattacks (Ascension and Change Healthcare). | 22.6 |
| Employee Turnover | Increased costs related to onboarding new personnel. | 42.1 |
| Long-term Debt | Total long-term debt as of September 30, 2024. | 2,140 |
| Net Interest Expense | Net interest expense for Q3 2024. | 43.2 |
| Net Loss | Net loss reported for Q3 2024. | 19.9 |
| Acquisition Costs | Costs incurred from the Acclara acquisition. | 662 |
| Customer Attrition | Revenue decrease from physician customer attrition. | 33.1 |
Future Growth Prospects for R1 RCM Inc. (RCM)
Future Growth Prospects for R1 RCM Inc.
Analysis of Key Growth Drivers
R1 RCM Inc. has identified several key growth drivers that are expected to propel its business forward. These include:
- Product Innovations: The company continues to enhance its revenue cycle management (RCM) services through technological advancements, which are projected to improve efficiency and customer satisfaction.
- Market Expansions: R1 RCM aims to expand its market presence, particularly through the integration of Acclara, which contributed approximately $199.1 million in revenue for the nine months ended September 30, 2024 .
- Acquisitions: The acquisition of Acclara for approximately $662.0 million is a significant step towards increasing market share and capabilities .
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, net services revenue increased by $209.5 million, or 12%, compared to the same period in 2023, reaching $1,888.6 million . This growth is largely attributed to new customer contracts valued at approximately $51.3 million .
Future revenue growth is projected to continue at a compound annual growth rate (CAGR) of 10.3% through 2030 in the U.S. RCM market . The anticipated revenue growth is supported by increasing demand for RCM services as healthcare providers seek to enhance operational efficiencies.
Strategic Initiatives or Partnerships
The company has engaged in strategic partnerships to bolster its service offerings. Notably, R1 RCM's focus on integrating advanced technology into its RCM processes is expected to streamline operations and reduce costs. The ongoing collaboration with healthcare providers aims to enhance service delivery and expand client bases .
Competitive Advantages
R1 RCM benefits from several competitive advantages that position it favorably for growth:
- Scale and Integration: The integration of Acclara provides enhanced scale, enabling the company to serve a broader client base more effectively .
- Technological Edge: Investments in technology allow for better data analytics and reporting capabilities, which are crucial for optimizing revenue cycles .
- Market Leadership: R1 RCM's established reputation and extensive experience in the RCM sector bolster its competitive positioning against both established players and new entrants .
Financial Overview
The following table summarizes key financial metrics relevant to R1 RCM's growth potential:
| Metric | 2024 (Projected) | 2023 (Actual) |
|---|---|---|
| Net Services Revenue | $1,888.6 million | $1,679.1 million |
| Cost of Services | $1,549.4 million | $1,328.1 million |
| Selling, General and Administrative Expenses | $184.9 million | $164.3 million |
| Net Income (Loss) | $(62.6) million | $1.9 million |
| Adjusted EBITDA | $456.5 million | $446.6 million |
In summary, R1 RCM is positioned well for future growth through strategic initiatives, market expansions, and leveraging its competitive advantages in the evolving healthcare landscape.
R1 RCM Inc. (RCM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- R1 RCM Inc. (RCM) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of R1 RCM Inc. (RCM)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View R1 RCM Inc. (RCM)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.